Mechanism of metformin action in MCF-7 and MDA-MB-231 human breast cancer cells involves oxidative stress generation, DNA damage, and transforming growth factor β1 induction

Tumor Biology

Volumn 37, Issue 4, 2016, Pages 5337-5346

  Marinello, Poliana Camila ^a   da Silva, Thamara Nishida Xavier ^a   Panis, Carolina ^a   Neves, Amanda Fouto ^a   Machado, Kaliana Larissa ^a   Borges, Fernando Henrique ^a   Guarnier, Flávia Alessandra ^a   Bernardes, Sara Santos ^a   de Freitas Junior, Júlio Cesar Madureira ^b   Morgado Díaz, José Andrés ^b   Luiz, Rodrigo Cabral ^a   Cecchini, Rubens ^a   Cecchini, Alessandra Lourenço ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Breast cancer; MCF 7; MDA MB 231; Metformin; Oxidative stress

Indexed keywords

METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA1; TGFB1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL DESTRUCTION; CELL DEATH; CELL GROWTH; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG EXPOSURE; DRUG MECHANISM; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MCF 7 CELL LINE; MDA MB 231 CELL LINE; METABOLIC ACTIVATION; MTT ASSAY; OXIDATIVE STRESS; PRIORITY JOURNAL; BIOSYNTHESIS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

APOPTOSIS; CELL PROLIFERATION; DNA DAMAGE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; METFORMIN; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84946761772     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4395-x     Document Type: Article

References (42)

1. Aksoy S, Sendur MA, Altundag K. Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin. Med Oncol. 2013;30(2):590–6.
2. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48(3):31–43.
3. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;67(22):10804–12.
4. Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko Y, Flomenberg N, Wang C, et al. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther. 2011;12(10):924–38.
5. Campagnoli C, Berrino F, Venturelli E, Abbà C, Biglia N, Brucato T, et al. Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin Breast Cancer. 2013;13(6):433–8.
6. Hadad SM, Hardie DG, Appleyard V, Thompson AM. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol. 2014;16(8):746–52.
7. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. Horm Metab Res. 2013;45(5):387–90.
8. Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012;2:362.
9. Malki A, Youssef A. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res. 2011;19(6):275–85.
10. Gago-Dominguez M, Jiang X, Castelao JE. Lipid peroxidation, oxidative stress genes and dietary factors in breast cancer protection: a hypothesis. Breast Cancer Res. 2007;9:201–12.
11. Panis C, Herrera AC, Victorino VJ, Campos FC, Freitas LF, De Rossi T, et al. Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat. 2012;133(1):89–97.
12. Queiroz EAIF, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. Plos One. 2014;9(5):e98207.
13. Ringnér M, Staaf J, Jonsson G. Nonfamilial breast cancer subtypes. Methods Mol Biol. 2013;973:279–95.
14. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, Mccue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer. 2007;110(4):876–84.
15. Barcellos-Hoff MH, Akhurst RJ. Transforming growth factor-β in breast cancer: too much, too late. Breast Cancer Res. 2009;11:202–8.
16. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4(4):257–62.
17. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005;102(38):13550–5.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation cytotoxic assays. J Immunol Methods. 1983;65:55–63.
19. Borenfreund E, Puerner JA. A simple quantitative procedure using monolayer cultures for cytotoxicity assays (HTD/NR-90). J Tissue Cult Methods. 1984;9(1):7–9.
20. Halliwell B, Gutteridge JMC. Free radical in biology and medicine. 4th ed. New York: Oxford University Press; 2007.
21. Michaeli A, Feitelson J. Reactivity of singlet oxygen toward amino acids and peptides. Photochem Photobiol. 1994;59:284–98.
22. Simic MG. Peroxyl radical from oleic acid. In: Simic MG, editor. Autoxidation in food and biological systems. New York: Plenum; 1980. p. 17–26.
23. Sun Y, Li Y, Wu H, Wu S, Wang YA, Luo D, et al. Effects of an indolocarbazole-derived CDK4 inhibitor on breast cancer cells. J Cancer. 2011;2:36–51.
24. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121–6.
25. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol. 1994;233:380–5.
26. Gonzalez-Flecha B, Llesuy S, Boveris A. Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver, and muscle. Free Radic Biol Med. 1991;10(2):93–100.
27. Victorino VJ, Panis C, Campos FC, Cayres RC, Colado-Simão AN, Oliveira SR, et al. Decreased oxidant profile and increased antioxidant capacity in naturally postmenopausal women. AGE. 2013;35:1411–21.
28. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen. 2000;35:206–21.
29. Hartmann A, Agurell E, Beevers S, Brendler-Schwaab S, Burlinson B, Clay P, et al. Recommendations for conducting the in vivo alkaline comet assay. Mutagenesis. 2003;18(1):45–51.
30. Wurth R, Barbieri F, Florio T. New molecules and old drugs as emerging approaches to selectively target human glioblastoma cancer stem cells. Biomed Res Int. 2014;2014:126586.
31. Lee H, Park HJ, Park CS, Oh ET, Choi BH, Williams B, et al. Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined. PLoS One. 2014;9(2):e87979.
32. Lin YC, Wu MH, Wei TT, Lin YC, Huang WC, et al. Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. Oncotarget. 2013;5(1):298–308.
33. Gonzalez-Ângulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2012;16(6):1695–700.
34. Zhuang Y, Miskimins WK. Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res. 2011;9(5):603–15.
35. Hadad SM, Hardie DG, Appleyard V, Thompson AM. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol. 2014;16:746–51.
36. Zordoky BNM, Bark D, Soltys CL, Sung MM, Dyck JRB. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim Biophys Acta. 2014;1840(6):1943–57.
37. Hasty P, Christy BA. p53 as an intervention target for cancer and aging. Pathobiol Aging Age Relat Dis. 2013;3:22702.
38. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci. 2001;114:4139–40.
39. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A. 2005;102(23):8204–9.
40. Santarpia L, Lippman SL, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103–19. doi:10.1517/14728222.2011.645805.
41. Krstic J, Trivanovic D, Mojsilovic S, Santibanez JF. Transforming growth factor-beta and oxidative stress interplay: implications in tumorigenesis and cancer progression. Oxid Med Cell Longev. 2015;2015(654594):15.
42. Qi S, den Hartog GJ, Bast A. Superoxide radicals increase transforming growth factor-beta1 and collagen release from human lung fibroblasts via cellular influx through chloride channels. Toxicol Appl Pharmacol. 2009;237(1):111–8.